Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review

Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment

(2020) David W Dodick et al.   CEPHALALGIA

Classification and mitigation of negative injection experiences with biologic medications

(2020) Jennifer M. Fernandez et al.   Dermatologic Therapy

Adherence to subcutaneous anti‐TNFα agents in patients with rheumatoid arthritis is largely influenced by pain and skin sensations at the injection site

(2020) Fausto Salaffi et al.   International Journal of Rheumatic Diseases

P620 Maintenance of clinical remission with SB5 biosimilar after switch from adalimumab originator: Real-life experience of a tertiary referral centre

(2020) G Dragoni et al.   Journal of Crohns & Colitis

P505 Different failure rates after non-medical switching of 744 patients from adalimumab originator to 2 different adalimumab biosimilars at Cambridge University Hospitals, UK: real-world experience

(2020) D Rosembert et al.   Journal of Crohns & Colitis

P473 Long-term follow-up of switching from original adalimumab to adalimumab biosimilar: real-world data in IBD

(2020) C Padilla Suarez et al.   Journal of Crohns & Colitis

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis

(2020) April W. Armstrong et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience

(2019) Bart J. F. van den Bemt et al.   DRUG DELIVERY

Usability of mepolizumab single-use prefilled syringe for patient self-administration

(2019) Elisabeth H. Bel et al.   JOURNAL OF ASTHMA

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

(2019) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Patient and physician preferences for attributes of biologic medications for severe asthma

(2019) Heather L Gelhorn et al.   Patient Preference and Adherence

Impact of pain associated with the subcutaneous administration of adalimumab

(2019) Cristina Gely et al.   Gastroenterologia y Hepatologia

Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site

(2019) Iris Usach et al.   ADVANCES IN THERAPY

Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

(2019) Vibeke Strand et al.   BIODRUGS

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

(2019) Joana Torres et al.   Journal of Crohns & Colitis

Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis

(2019) Elsie Grace et al.   Dermatology and Therapy

Role of biological agents in treatment of rheumatoid arthritis

(2019) Shing T. Law et al.   PHARMACOLOGICAL RESEARCH

Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study

(2018) G. Girolomoni et al.   BRITISH JOURNAL OF DERMATOLOGY

P497 Injection site reactions and injection site pain for the adalimumab biosimilar ABP 501: Results from two double-blind, randomised, controlled studies

(2018) E Krishnan et al.   Journal of Crohns & Colitis

Buffered local anesthetics reduce injection pain and provide anesthesia for up to 5 hours

(2018) Josefine Bunke et al.   Journal of Plastic Reconstructive and Aesthetic Surgery

Pain Catastrophizing, Subjective Outcomes, and Inflammatory Assessments Including Ultrasound: Results From a Longitudinal Study of Rheumatoid Arthritis Patients

(2018) Hilde B. Hammer et al.   ARTHRITIS CARE & RESEARCH

Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study

(2018) Séverine Vermeire et al.   Patient Preference and Adherence

Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities

(2018) Beate Bittner et al.   BIODRUGS

The nocebo effect: a clinical challenge in the era of biosimilars

(2018) Lieven Pouillon et al.   Expert Review of Clinical Immunology

Are Injection Site Reactions in Monoclonal Antibody Therapies Caused by Polysorbate Excipient Degradants?

(2018) Satish K. Singh et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies

(2018) Virginia Stauffer et al.   Patient Preference and Adherence

Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis

(2018) Jeehoon Ghil et al.   CURRENT MEDICAL RESEARCH AND OPINION

Injectability as a function of viscosity and dosing materials for subcutaneous administration

(2018) Russell P. Watt et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Old and New Biological Therapies for Psoriasis

(2017) Kirsten Rønholt et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

(2017) Marcus Harbord et al.   Journal of Crohns & Colitis

Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira®in healthy subjects

(2016) Elizabeth Hyland et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes

(2016) Oliver von Richter et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Growth hormone delivery devices: current features and potential for enhanced treatment adherence

(2016) Tilman R. Rohrer et al.   Expert Opinion on Drug Delivery

Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis

(2016) Barbara Domańska et al.   Expert Opinion on Drug Delivery

Subcutaneous Injection Volume of Biopharmaceuticals—Pushing the Boundaries

(2016) Roman Mathaes et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects

(2015) Clapton Dias et al.   AAPS PHARMSCITECH

Simple Psychological Interventions for Reducing Pain From Common Needle Procedures in Adults

(2015) Katelynn E. Boerner et al.   CLINICAL JOURNAL OF PAIN

Tolerability of hypertonic injectables

(2015) Wei Wang   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective

(2015) Susan Bolge et al.   Patient Preference and Adherence

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

(2015) Jasvinder A. Singh et al.   Arthritis & Rheumatology

GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis

(2015) Jerry S. Wolinsky et al.   Multiple Sclerosis and Related Disorders

Biologics in inflammatory bowel disease: what are the data?

(2015) Justin Côté-Daigneault et al.   United European Gastroenterology Journal

Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial

(2014) T. Heise et al.   DIABETES OBESITY & METABOLISM

The role of excess subcutaneous fat in pain and sensory sensitivity in obesity

(2013) R.C. Price et al.   EUROPEAN JOURNAL OF PAIN

Educational session as a tool to increase patient satisfaction of switching etanercept from the prefilled syringe to the autoinjection pen

(2013) Joaquín Borrás-Blasco et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Selective TNF-α inhibitor-induced injection site reactions

(2013) Giuseppe Murdaca et al.   Expert Opinion On Drug Safety

Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study

(2012) Barry Singer et al.   BMC Neurology

An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects

(2011) J Theodore Phillips et al.   BMC Neurology

Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ)

(2011) Dorothy Keininger et al.   Health and Quality of Life Outcomes

Judging Pain Sensitivity with Subcutaneous Lidocaine Injections

(2011) Eileen R. Manabat et al.   PAIN MEDICINE

Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologics

(2010) Jeffrey R. Curtis et al.   CURRENT MEDICAL RESEARCH AND OPINION

Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study

(2010) G. Anderson et al.   JOURNAL OF NEUROLOGY

Underappreciated medication contraindication

(2010) Alicia J. Zbehlik et al.   ARTHRITIS CARE & RESEARCH

A systematic review of measures for reducing injection pain during adult immunization

(2009) Mary-Ellen Hogan et al.   VACCINE

A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease

(2008) Simon D. Roger et al.   CURRENT MEDICAL RESEARCH AND OPINION

Existe-t-il des différences d’immunogénicité et de tolérance des vaccins en fonction du mode d’injection ?

(2008) F. Ajana et al.   MEDECINE ET MALADIES INFECTIEUSES